Afinitor Extends PFS by 7.1 Months in Gastrointestinal and Lung NETs

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

October 04, 2024

Vol.50 No.37

By Jacquelyn Cobb

Conversation with The Cancer Letter

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Every summer since 2010, ten undergraduate students from diverse backgrounds get the opportunity to explore any curiosities they might have about careers in medicine at Memorial Sloan Kettering Cancer Center.

October 04, 2024

Vol.50 No.37

By Claire Marie Porter

Guest Editorial

NCI-designated Basic Laboratory Cancer Centers get research done—efficiently

Having had the honor and pleasure to lead an NCI-designated cancer center for several years, I would like to share my thoughts on this small yet unique set of institutes and their value to NCI and the nation.

October 04, 2024

Vol.50 No.37

By Ze’ev Ronai

Cancer History Project Conversation with The Cancer Letter

Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer

On Nov. 24, 2003, an article in The Boston Globe told the story of a patient’s remarkable response to gefitinib, a drug that had recently been approved by FDA.

October 04, 2024

Vol.50 No.37

By Paul Goldberg and McKenzie Prillaman

In the Archives

Jeffrey Weber on his career, mentors: “Never ever ever ever blow your cool.”

In 2023, Jeffrey S. Weber was named a Fellow of the Academy of Immuno-Oncology, an honor established by the Society for Immunotherapy of Cancer. Weber died Aug. 18, 2024 (The Cancer Letter, Sept. 6, 2024). After receiving the accolade from SITC, Weber sat down with the society to reflect on his career. He discussed what...

October 04, 2024

Vol.50 No.37

In Brief

Kevin Holcomb joins Northwell as chair of obstetrics and gynecology

Kevin Holcomb will join Northwell Health as chair of the Department of Obstetrics and Gynecology at North Shore University Hospital in Manhasset, Long Island Jewish Medical Center in New Hyde Park, and The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale.

October 04, 2024

Vol.50 No.37

Afinitor Extends PFS by 7.1 Months in Gastrointestinal and Lung NETs

YOU MAY BE INTERESTED IN

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

NCI-designated Basic Laboratory Cancer Centers get research done—efficiently

Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer

Jeffrey Weber on his career, mentors: “Never ever ever ever blow your cool.”

Kevin Holcomb joins Northwell as chair of obstetrics and gynecology

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

Afinitor Extends PFS by 7.1 Months in Gastrointestinal and Lung NETs

YOU MAY BE INTERESTED IN

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitorsVote may lead to rollback of some indications held by BMS and Merck

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

NCI-designated Basic Laboratory Cancer Centers get research done—efficiently

Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer

Jeffrey Weber on his career, mentors: “Never ever ever ever blow your cool.”

Kevin Holcomb joins Northwell as chair of obstetrics and gynecology

Can you spare 10 minutes to complete a survey?

Login

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck